Wilson Sonsini Goodrich & Rosati represented Alpine, while Latham & Watkins represented to underwriters in the offering. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) has announced the pricing...
Alpine Immune Sciences’ $100 Million Shares Offering
East Resources Acquisition Company’s Combination With Abacus Settlements and Longevity Market Assets
Latham & Watkins represented East Resources Acquisition Company, while Locke Lord represented Abacus in the transaction. Abacus Settlements, LLC (d/b/a Abacus Life) and Longevity Market Assets,...
Health Care Service Corporation’s Acquisition of Trustmark Health Benefits
Foley & Lardner LLP represented Health Care Service Corporation (HCSC) on the deal, while Latham & Watkins LLP represented Trustmark in the transaction. Health Care Service Corporation...
Arcutis Biotherapeutics’ $150 Million Shares Offering
Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten...
Amgen’s $3.7 Billion Acquisition of ChemoCentryx
Wachtell, Lipton, Rosen & Katz represented Amgen, while Latham & Watkins represented ChemoCentryx in the transaction. Amgen and ChemoCentryx, Inc., a biopharmaceutical company focused on orally...
Patient Square Capital’s $1.25 Billion Acquisition of Hanger
Kirkland & Ellis, Greenberg Traurig, and Latham & Watkins advised Patient Square Capital, Foley & Lardner advised Hanger, Proskauer Rose advised Ares Capital Management LLC on...
Revolution Medicines’ $230 Million Shares Offering
Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering. Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten...
Lindsay Goldberg’s Investment into MMS Holdings
Latham & Watkins represented Lindsay Goldberg in the transaction. MMS Holdings Inc. (MMS), a leading data-focused contract research organization (CRO), has announced that Lindsay Goldberg, a...
Rhythm Pharmaceuticals’ $100 Million Revenue Interest Financing Agreement With HealthCare Royalty Partners
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
Pfizer’s $25 Million Equity Investment in Zentalis Pharmaceuticals
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological...
Ligand’s Spin-off of OmniAb Business
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...
Clarify Health’s Acquisition of Embedded Healthcare
Latham & Watkins represented Clarify Health in the transaction. Clarify Health, a leading cloud analytics and value-based payments platform company, has announced the acquisition of Embedded...